Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
119P Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India Background: Patients with advanced breast cancer are usually resistant to anthracyclines and taxanes. Treatment failure is observed in majority of metastatic breast cancer patients and 5 year survival rate is only 27%. Treatment guidelines do not recommend any single agent or a combination regimen in particular sequence for advanced breast cancer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
